



## Letter to the Editor

**Reply to the reply of the authors of the review article entitled "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy"**



## To The Editor

We would like to comment on the reply of the authors of the review article entitled "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy" [1]. In particular, it should be clarified that buccal midazolam is not only reimbursed but that its use has been approved for this indication in Italy (it is not off-label) in adults who started taking the drug before the age of 18 years. The second critical point [2] has not been adequately clarified. In their article (Paragraph 4.2.1., initial status epilepticus [SE]), the use of intravenous midazolam is proposed by the authors to treat the initial SE, without the indication that its use is off-label in Italy. So, it should be specified that the intravenous or intramuscular use of midazolam is off-label to treat all the types of SE in adults, and not only the refractory subtype. This should be clearly stated in the reply also for the possible legal consequences. In conclusion, even if this reply contains some useful clarifications, we think that it should be revised, in particular, according to the Italian regulatory scenario. The ultimate goal is always to allow patients to benefit from standard of care avoiding both the inappropriate use of medicines and unjustified concerns in people with epilepsy.

## References

- [1] Minicucci F, Ferlisi M, Brigo F, Mecarelli O, Meletti S, Aguglia U, et al. Reply to Dr. Capovilla on "Reply to the article "Management of status epilepticus in adults. Position paper of the Italian League Against Epilepsy"". *Epilepsy Behav.* 2020 Apr 6:107048. <https://doi.org/10.1016/j.yebeh.2020.107048> [Epub ahead of print. No abstract available. PMID: 32268969].
- [2] Capovilla G, Nistico R, Magrelli A. Reply to the article "Management of status epilepticus in adults. Position paper of the Italian League against Epilepsy". *Epilepsy Behav.* 2020 Jan 22:106866. <https://doi.org/10.1016/j.yebeh.2019.106866> [Epub ahead of print. No abstract available. PMID:31982343].

Giuseppe Capovilla

*Epilepsy Center, C. Poma Hospital, Mantova, Italy  
Fondazione Poliambulanza, Brescia, Italy*

\*Corresponding author at: Epilepsy Center, C. Poma Hospital,  
Mantova, Italy

Email address: [giuseppe.capovilla@asst-mantova.it](mailto:giuseppe.capovilla@asst-mantova.it)

Robert Nistico

*School of Pharmacy, University of Rome "Tor Vergata", Rome, Italy  
Neuropharmacology Lab, European Brain Research Institute, Rome, Italy*

Armando Magrelli

*Centro Nazionale Valutazione Preclinica e Clinica dei Farmaci, Istituto  
Superiore di Sanità, Roma, Italy*

5 May 2020